Question 1

What is ATG-201?

Accepted Answer

ATG-201 is a Other.

Question 2

How often does ATG-201 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 8 articles.

Question 3

When was ATG-201 first tracked by Ergen?

Accepted Answer

First tracked on Jun 10, 2026.

Question 4

When was ATG-201 last mentioned in news?

Accepted Answer

Last active on Jun 10, 2026.

Question 5

What is ATG-201's current news sentiment?

Accepted Answer

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is ATG-201 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving ATG-201?

Accepted Answer

Antengene ATG-201 IND Approval China (Jun 10, 2026, 8 articles).

Question 8

How did the "Antengene ATG-201 IND Approval China" event impact ATG-201?

Accepted Answer

ATG-201, a CD19/CD3 bispecific T-cell engager antibody, received IND approval for Phase I clinical trials in China for B cell related autoimmune diseases. This approval is a crucial step in its development and potential commercialization.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.